Select Publications
Journal articles
, 2025, 'Author Correction: Bullous pemphigoid (Nature Reviews Disease Primers, (2025), 11, 1, (12), 10.1038/s41572-025-00595-5)', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00605-6
, 2025, 'Bullous pemphigoid', Nature Reviews Disease Primers, 11, http://dx.doi.org/10.1038/s41572-025-00595-5
, 2025, 'Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: Results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up)', British Journal of Dermatology, 193, pp. 1101 - 1111, http://dx.doi.org/10.1093/bjd/ljaf236
, 2025, 'Enhancing randomized clinical trials with digital twins', Npj Systems Biology and Applications, 11, http://dx.doi.org/10.1038/s41540-025-00592-0
, 2025, 'Morgellons disease: a review on current evidence and the need for consensus, standardized criteria, and future randomized controlled trials', Archives of Dermatological Research, 317, http://dx.doi.org/10.1007/s00403-025-04308-6
, 2025, 'Erratum: Author Correction: Enhancing randomized clinical trials with digital twins (NPJ systems biology and applications (2025) 11 1 DOI: 10.1038/s41540-025-00592-0.)', Npj Systems Biology and Applications, 11, pp. 124, http://dx.doi.org/10.1038/s41540-025-00609-8
, 2025, 'Standardized indirect immunofluorescence-based detection of dermal-binding autoantibodies in pemphigoid diseases: a prospective international multicentre study', BRITISH JOURNAL OF DERMATOLOGY, http://dx.doi.org/10.1093/bjd/ljaf385
, 2025, 'Ofatumumab for the management of refractory pemphigus vulgaris: A case series', Jaad International, 22, pp. 94 - 96, http://dx.doi.org/10.1016/j.jdin.2025.05.018
, 2025, 'Evaluation of the responsiveness of the Keratosis Pilaris Investigator Global Assessment Score (KP-IGA) and composite KP Area Index (KPAI)', British Journal of Dermatology, 193, pp. 556 - 558, http://dx.doi.org/10.1093/bjd/ljaf163
, 2025, 'Linear Focal Elastosis: What We Know From Epidemiological Studies', Australasian Journal of Dermatology, 66, pp. 364 - 368, http://dx.doi.org/10.1111/ajd.14569
, 2025, 'Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External Experts', International Journal of Dermatology, 64, pp. 1546 - 1557, http://dx.doi.org/10.1111/ijd.17668
, 2025, 'Reduction in Dressing Change Burden in Patients With Epidermolysis Bullosa—Impact of Oleogel-S10', Journal of Dermatology, 52, pp. 1447 - 1451, http://dx.doi.org/10.1111/1346-8138.17884
, 2025, 'Space Oncology: A Comprehensive Scoping Review', Wilderness and Environmental Medicine, 36, pp. 148 - 171, http://dx.doi.org/10.1177/10806032251349442
, 2025, 'Dr. Dedee Murrell', The Nishinihon Journal of Dermatology, 87, pp. 369 - 370, http://dx.doi.org/10.2336/nishinihonhifu.87.369
, 2025, 'The Efficacy of Using Oral Sodium Cromoglycate for Controlling Epidermolysis Bullosa-Related Pruritus', Australasian Journal of Dermatology, 66, pp. 309 - 311, http://dx.doi.org/10.1111/ajd.14530
, 2025, 'Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres', Australasian Journal of Dermatology, 66, pp. 305 - 308, http://dx.doi.org/10.1111/ajd.14532
, 2025, 'Colchicine as a treatment option for inherited epidermolysis bullosa', Clinical and Experimental Dermatology, 50, pp. 1238 - 1240, http://dx.doi.org/10.1093/ced/llaf016
, 2025, 'Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study', British Journal of Dermatology, 192, pp. 1007 - 1017, http://dx.doi.org/10.1093/bjd/ljaf022
, 2025, 'Translation, cultural adaptation and validation of the German Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire', Journal of Health Psychology, 30, pp. 1476 - 1490, http://dx.doi.org/10.1177/13591053231221369
, 2025, 'Dermatologic manifestations of hereditary hemochromatosis: A systematic review', Journal of the European Academy of Dermatology and Venereology, 39, pp. 976 - 986, http://dx.doi.org/10.1111/jdv.20098
, 2025, 'Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires', Journal of Dermatology, 52, pp. 812 - 830, http://dx.doi.org/10.1111/1346-8138.17707
, 2025, 'Leveraging space innovations for cancer breakthroughs on Earth', Trends in Cancer, 11, pp. 433 - 440, http://dx.doi.org/10.1016/j.trecan.2025.02.003
, 2025, 'Linear IgA Bullous Dermatosis in Adults and Children: A Narrative Review of Literature on Disease Distribution and Evaluation of Existing Scoring Tools', Acta Dermatovenerologica Croatica ADC, 33, pp. 1 - 8
, 2025, 'The development and validation of an investigator global assessment score for keratosis pilaris', Journal of the European Academy of Dermatology and Venereology, 39, pp. e350 - e352, http://dx.doi.org/10.1111/jdv.20326
, 2025, 'Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece', Jid Innovations, 5, http://dx.doi.org/10.1016/j.xjidi.2024.100339
, 2025, 'Assessment of a Real-Time PCR Assay for the Detection of Dermatophytosis by Sampling With an Adhesive Tape Technique', Australasian Journal of Dermatology, 66, pp. e60 - e61, http://dx.doi.org/10.1111/ajd.14415
, 2025, 'Ethics of publication mills and payment for guaranteed authorships', Journal of the American Academy of Dermatology, 92, pp. 666 - 667, http://dx.doi.org/10.1016/j.jaad.2024.10.034
, 2025, 'Toward gender equity for all members of the academic dermatology community', Clinics in Dermatology, 43, pp. 248 - 250, http://dx.doi.org/10.1016/j.clindermatol.2025.01.004
, 2025, 'Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy', Journal of the European Academy of Dermatology and Venereology, 39, pp. 340 - 349, http://dx.doi.org/10.1111/jdv.20149
, 2025, 'Body image disturbance has severe psychosocial impacts in patients suffering from autoimmune blistering diseases', Journal of the European Academy of Dermatology and Venereology, 39, pp. 253 - 254, http://dx.doi.org/10.1111/jdv.20491
, 2025, 'Bullous pemphigoid burden of disease, management and unmet therapeutic needs', Journal of the European Academy of Dermatology and Venereology, 39, pp. 290 - 300, http://dx.doi.org/10.1111/jdv.20313
, 2025, 'Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real-World Clinical Outcomes and Lipid Profile Evaluation', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14592
, 2025, 'Pilot Study of Tildrakizumab in the Treatment of Stable Non-Segmental Vitiligo', JEADV Clinical Practice, http://dx.doi.org/10.1002/jvc2.70113
, 2025, 'Quality of Life Measurement in Autoimmune Blistering Diseases: Mutual Position Statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Autoimmune Blistering Diseases', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17964
, 2024, 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council', British Journal of Dermatology, 192, pp. 135 - 143, http://dx.doi.org/10.1093/bjd/ljae342
, 2024, '“Quality of Life in Epidermolysis Bullosa” and “Epidermolysis Bullosa Burden of Disease”: Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires', Italian Journal of Pediatrics, 50, http://dx.doi.org/10.1186/s13052-024-01657-2
, 2024, 'A new dawn for orphan diseases in dermatology: The transformative potential of digital twins', Journal of the European Academy of Dermatology and Venereology, 38, pp. 2309 - 2310, http://dx.doi.org/10.1111/jdv.20062
, 2024, 'Digital twins in dermatology, current status, and the road ahead', Npj Digital Medicine, 7, http://dx.doi.org/10.1038/s41746-024-01220-7
, 2024, 'Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)', Advances in Therapy, 41, pp. 4418 - 4432, http://dx.doi.org/10.1007/s12325-024-02992-w
, 2024, 'The future of digital pills and their potential use in dermatological clinical trials', Journal of the European Academy of Dermatology and Venereology, 38, pp. 2314 - 2315, http://dx.doi.org/10.1111/jdv.20224
, 2024, 'A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists', Clinics in Dermatology, 42, pp. 723 - 726, http://dx.doi.org/10.1016/j.clindermatol.2024.05.008
, 2024, 'Establishing minimal clinically important differences for the Pemphigus Disease Area Index', British Journal of Dermatology, 191, pp. 823 - 831, http://dx.doi.org/10.1093/bjd/ljae283
, 2024, 'Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial', Eclinicalmedicine, 77, http://dx.doi.org/10.1016/j.eclinm.2024.102900
, 2024, 'Keratosis pilaris treatment paradigms: Assessing effectiveness across modalities', Clinical and Experimental Dermatology, 49, pp. 1105 - 1117, http://dx.doi.org/10.1093/ced/llae066
, 2024, 'Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being', Australasian Journal of Dermatology, 65, pp. e145 - e155, http://dx.doi.org/10.1111/ajd.14308
, 2024, 'Dermatology Journal Advisory Boards and editorial independence', Jaad International, 16, pp. 224 - 236, http://dx.doi.org/10.1016/j.jdin.2023.08.001
, 2024, 'Letter to the editor in reply to “A call for action: Formalin exposure and broader occupational hazards and assessing the risk of glioblastoma in clinician scientists”', Clinics in Dermatology, 42, pp. 526 - 527, http://dx.doi.org/10.1016/j.clindermatol.2024.07.002
, 2024, 'Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions', Journal of the European Academy of Dermatology and Venereology, 38, pp. e747 - e749, http://dx.doi.org/10.1111/jdv.19863
, 2024, 'Patient-reported outcomes and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the GLOBOSTAD multinational prospective observational study', BRITISH JOURNAL OF DERMATOLOGY, 191, http://dx.doi.org/10.1093/bjd/ljae266.016
, 2024, 'Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study', Journal of Investigative Dermatology, 144, pp. 1762 - 1771.e6, http://dx.doi.org/10.1016/j.jid.2024.02.023